Medtronic recently began a clinical study to evaluate the safety and effectiveness of the Endurant Evo abdominal aortic aneurysm (AAA) stent graft system, an investigational medical device designed to expand the applicability of a minimally invasive alternative to open surgical repair for the treatment of abdominal aortic aneurysms.
Spectranetics is accelerating investments in the Stellarex drug-coated balloon angioplasty platform for treatment of below-the-knee peripheral artery disease. The company estimates this will represent a $150m market opportunity by 2020.
Medtronic has announced the start of a new feasibility study to evaluate the safety and effectiveness of the Valiant Mona LSA branch thoracic stent graft system, an investigational medical device designed to enable a completely endovascular solution for aortic aneurysms encroaching on the left subclavian artery.
Intact Vascular has announced that it has raised US$38.9 million in a series B venture capital financing. The funds will be used to accelerate the development and FDA approval of the company’s Tack Endovascular System. The latest round, one of the largest private medical technology financings of 2015, was led by New Enterprise Associates (NEA), with participation from Quaker Partners, HIG BioVentures and other existing investors.
Forge Medical, manufacturer of the VasoStat haemostasis device that is used for radial artery and dialysis access haemostasis, announced that the company has entered into a national commercialisation agreement for the device with National Medical Sales.
The study was presented at the Society of Interventional Radiology’s annual scientific meeting (28 February–5 Atlanta, USA). Aaron Fischman, Department of Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, USA, spoke to Interventional News.
Boston Scientific has announced that it is taking a new approach to evaluate the performance of its Vessix renal denervation system—it is initiating a study with a novel design to isolate the effects of the therapy in patients with high blood pressure. The REDUCE-HTN: REINFORCE randomised, sham-controlled, multicentre study is designed to isolate and demonstrate the effects of the Vessix renal denervation system by minimising variability and factors that may have affected results in SYMPLICITY HTN-3.
Silk Road Medical has announced the first US commercial procedure using the Enroute transcarotid neuroprotection system was successfully performed at Mills-Peninsula Medical Center in Burlingame, USA by vascular surgeon John E Rosenman.
Many nursing home residents who underwent lower extremity revascularization died, did not walk or had functional decline following the procedure, which is commonly used to treat leg pain caused by peripheral arterial disease, wounds that will not heal or worsening gangrene, according to an article published online by JAMA Internal Medicine.
In experienced hands, non-target embolization is rare, a study presented at the European Congress of Radiology (ECR, 4–8 March, Vienna, Austria) concluded.
A study presented at the Society of Interventional Radiology’s (SIR’s) 2015 annual scientific meeting reveals that a new angiographic imaging platform (AlluraClarity, Philips Healthcare) maintains similar procedure time as a current C-arm imaging platform (Allura, Philips), yet with substantially reduced radiation exposure for uterine artery embolization procedures.
Terumo has announced that on 16 March 2015 it received CE mark for LifePearl, a new drug-eluting microsphere for chemoembolization and HydroPearl, a new microsphere for more predictable bland embolization.
Medtronic has announced the initiation of the SPYRAL HTN global clinical trial programme, a phased clinical programme studying renal denervation in uncontrolled hypertension. This announcement follows investigational device exemption approval by the US Food and Drug Administration (FDA).
A rapid overview of three of these treatments: ablation, chemoembolization and selective interval radiation therapy, should help clarify the challenges and difficulties of determining tumour response in interventional oncology, write Maxime Ronot and Valérie Vilgrain.
In the past five years we have treated more than 400 patients for uterine fibroids, bone metastasis and osteoid osteoma in routine practice with significant clinical results and negligible adverse events, but therapeutic ultrasound still has some technological hurdles that need to be overcome, writes Alessandro Napoli.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos